Waylivra has been approved as the first treatment for familial partial lipodystrophy in Brazil.
The BBV154 vaccine is approved for the first two-dose schedule and homologous booster doses.
Cell therapies and regenerative medicine have enormous potential to change the way we treat patients and deliver health care, but the production of cells on a reproducible commercial scale poses a challenge.
Cut drug wastage, reduce risk, and optimise supply with advanced, integrated technologies designed to deliver increased visibility, flexibility and accuracy.
The Canadian Government will receive 15,000 courses of Actemra IV from Roche.
Get industry leading news, data and analysis delivered to your inbox
The boards of directors of both companies have granted approval for the merger.
The approval is based on the findings from the clinical programme including data from the Phase III PUNCH CD3 trial.
The funds are intended to advance the vaccines to the successful conclusion of Phase I clinical trials.
Pharmaceutical Technology analyzes recent regulatory decisions by several authorities that will likely impact therapy manufacturing plans.
Driven by changing regulations and an increased need for quality, traceability, and efficiency, the pharmaceutical industry is upgrading how it performs container closure integrity tests.
The current MS pipeline offers new hope for pre-progressive MS (PPMS) patients, with three late-stage agents in development.
The FDA has granted Mounjaro a Fast Track designation to treat obesity, as it has shown comparable potential to gastric bypass surgery.
Following the closing of the deal, Viatris president Rajiv Malik has joined Biocon Biologics’ board of directors.
The latest approval in the EU is based on data from an open-label clinical trial of Biktarvy.
In addition to removing tumour cells at the injection site, the treatment demonstrated an abscopal effect.